SOURCE: Prima BioMed (Published by http://www.marketwatch.com/)
SYDNEY, AUSTRALIA, May 11, 2015 (Marketwired via COMTEX) -- Prima BioMed Ltd (asx:PRR) PBMD, +3.88% ("Prima" or the "Company") announces a collaboration with NEC Corporation and Yamaguchi University for Immutep's IMP321 in combination with a peptide vaccine developed by NEC and Yamaguchi University.
The preclinical study, to be conducted at Yamaguchi University and supported by NEC, will investigate the use of antigen presenting cell activator IMP321 as an adjuvant, together with peptide antigens believed to be involved in hepatocellular cancer.
Marc Voigt, Chief Executive of Prima, said: "We are very pleased to be able to assist NEC with this preclinical study. The use of IMP321 as an adjuvant to a vaccine is different to the other combination approaches being used for our planned clinical trials. The opportunity to broaden the application of IMP321 for other uses is exciting."
Yamaguchi University President Dr Masaaki Oka, MD, commented: "We look forward to working on this program and exploring the use of IMP321 together with our vaccine. We believe that this combination could offer a unique treatment opportunity."
The preclinical study, to be conducted at Yamaguchi University and supported by NEC, will investigate the use of antigen presenting cell activator IMP321 as an adjuvant, together with peptide antigens believed to be involved in hepatocellular cancer.
Marc Voigt, Chief Executive of Prima, said: "We are very pleased to be able to assist NEC with this preclinical study. The use of IMP321 as an adjuvant to a vaccine is different to the other combination approaches being used for our planned clinical trials. The opportunity to broaden the application of IMP321 for other uses is exciting."
Yamaguchi University President Dr Masaaki Oka, MD, commented: "We look forward to working on this program and exploring the use of IMP321 together with our vaccine. We believe that this combination could offer a unique treatment opportunity."
Read more: http://www.marketwatch.com/story/prima-biomed-announces-japanese-collaboration-2015-05-11